89bio, Inc.
NASDAQ: ETNB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rohan Palekar
- Employees
- 93
- Headquarters
- San Francisco, United States
- IPO year
- 2019
- Market cap
- $2.2B
- Website
- https://www.89bio.com
Loading ETNB…
Loading profile data…Frequently asked questions about ETNB
What does 89bio, Inc. (ETNB) do?
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic stea...
Where does ETNB trade?
89bio, Inc. (ETNB) trades on the NASDAQ Global Market.
What sector is ETNB in?
89bio, Inc. (ETNB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of 89bio, Inc.?
Rohan Palekar is the chief executive officer of 89bio, Inc. (ETNB).
Where is 89bio, Inc. headquartered?
89bio, Inc. is headquartered in United States.
Does ETNB pay a dividend?
89bio, Inc. (ETNB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ETNB go public?
89bio, Inc. (ETNB) completed its initial public offering in 2019.